Rightware Releases Kanzi One, the First All-in-One Automotive HMI Tool for the Advanced Intelligent Cockpit
4.1.2022 10:00:00 EET | Business Wire | Press release
Rightware today released Kanzi One, concluding a highly successful and oversubscribed beta program announced in September. The first automotive HMI toolchain to be fully compatible with Android™, Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005425/en/
Rightware today released Kanzi One, the first automotive HMI toolchain to be fully compatible with Android™. Kanzi One delivers industry-leading 3D graphics and a new UI workflow, empowering automakers to create compelling new user experiences with visual excellence and maximum productivity. (Photo: Business Wire)
“As announced at IAA in Munich, Kanzi One is a game-changer for creativity and productivity by automakers,” said Rightware CEO Freddie Geier. “We are grateful for the positive feedback from customers and partners since our product launch, and we eagerly await the new Signature UIs they create with Kanzi One.”
Rightware’s goal with Kanzi One is to inspire OEMs and Tier 1 suppliers with impressive rendering capabilities and a powerful 3D graphics engine, the deepest Android integration for next generation infotainment systems, and a straightforward workflow that unleashes HMI possibilities.
Kanzi One lets manufacturers deliver future-looking user experiences for advanced HMIs in less than half the time with teams half the size and with significantly less coding compared with traditional methods.
All-in-One Solution
In addition to the core Kanzi framework consisting of Kanzi Studio and Kanzi Engine, Kanzi One delivers further value to automakers by including a growing list of feature packs.
Initially, five feature packs are included: Kanzi Connect makes it easy to share data, content, and services across screens and devices; Kanzi Maps enhances navigation with creative visualization; Kanzi Particles enables astounding visual effects and animations; Kanzi Autostereoscopy enables realistic depth effects; and the new Kanzi VR makes it easy to validate designs in an early phase by placing live UIs inside a virtual car interior and interacting with the screens with or without a virtual reality headset.
“We are certain that Kanzi One will transform the in-car user interfaces of today into tomorrow’s Signature UIs—highly appealing, easy-to-use, and true to their brand,” said Geier. “We invite all friends and observers of innovation in the automotive industry to explore the possibilities of Kanzi One, and count on us to drive HMI development to the next level.”
Due to the rapidly rising health risks associated with covid, Rightware made the decision not to attend CES 2022. Instead, the company will kick off a customer road show to present Kanzi One as conditions permit. To request a virtual or in-person meeting and to read descriptions of the latest Kanzi One demonstrations, please visit www.rightware.com/kanzi-one-at-ces-2022 or contact sales@rightware.com.
About Rightware
Rightware is the company behind the Kanzi family of tools and services for design and development of advanced digital user interfaces. Our mission is to help automakers increase brand value with highly customized signature user interfaces. As a ThunderSoft company, our combined skills and assets allow us to deliver fully integrated HMI solutions, engineering support, and design services. Rightware is headquartered in Finland and has a presence in China, Germany, Italy, Japan, South Korea, UK, and USA. Kanzi is the market-leading automotive UI tool trusted by over 50 automotive brands across the globe. www.rightware.com
Android is a trademark of Google LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005425/en/
Contact information
Derek Sellin
Vice President, Marketing
Rightware
press@rightware.com
John Tews
The Millerschin Group
248-320-3814
jtews@millerschingroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom